可溶性ST2在成人先天性心脏病患者中的预后价值
这项前瞻性队列研究纳入602例成人先天性心脏病(ACHD)门诊患者,检测可溶性ST2(sST2)并与复合终点(全因死亡、心衰、住院、心律失常、血栓栓塞事件或心脏干预)进行关联分析。中位随访5.8年,225例(38.5%)达到主要终点;sST2在调整年龄、性别、肌酐和NT-proBNP后与终点显著相关,但进一步调整临床变量和NT-proBNP后关联减弱;在复杂ACHD和女性中关联显著。
要点
- sST2在ACHD中与复合终点关联,但独立于临床变量和NT-proBNP的关联仅在复杂ACHD和女性中显著。
- 女性中sST2每升高两倍,终点风险HR 1.80(95%CI 1.30-2.49,p<0.001),男性不显著。
- 复杂ACHD中调整临床变量和NT-proBNP后,sST2每升高两倍HR 1.31(95%CI 1.01-1.69,p=0.043)。
核心结论
- sST2是ACHD中有前景的新型生物标志物,尤其在复杂ACHD和女性中。
研究设计与样本
- 前瞻性队列研究,纳入2011-2013年连续602例ACHD门诊患者,sST2在590例(98%)中可测。
主要发现
- 中位随访5.8年(IQR 5.1-6.2),225例(38.5%)达到主要复合终点。
- 调整年龄、性别、肌酐和NT-proBNP后,sST2每升高两倍与主要终点显著相关(HR 1.28,95%CI 1.03-1.58,p=0.025)。
- 进一步调整临床变量和NT-proBNP后,关联不再显著(HR 1.19,95%CI 0.96-1.48,p=0.106)。
- 复杂ACHD中调整临床变量和NT-proBNP后,sST2每升高两倍与主要终点显著相关(HR 1.31,95%CI 1.01-1.69,p=0.043)。
- 女性中sST2每升高两倍与主要终点显著相关(HR 1.80,95%CI 1.30-2.49,p<0.001),男性不显著(HR 1.19,95%CI 0.90-1.56,p=0.223)。
临床怎么用
- 在ACHD风险分层中可考虑检测sST2,尤其对复杂ACHD和女性患者可能提供额外预后信息。
局限性
- sST2独立于临床变量和NT-proBNP的关联在整体队列中不显著,需未来研究阐明性别和诊断特异性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Soluble suppression of tumourigenicity-2 (sST2) is upregulated as response to myocardial stress and may be a potential biomarker for risk stratification in patients with adult congenital heart disease (ACHD). This study aimed to investigate the release of sST2 and its association with cardiovascular events in ACHD. METHODS: In this prospective cohort study, 602 consecutive patients with ACHD visiting the outpatient clinic were included (2011-2013). The association between sST2 and a primary composite endpoint of all-cause mortality, heart failure, hospitalisation, arrhythmia, thromboembolic events or cardiac interventions was investigated using multivariable Cox regression. RESULTS: sST2 was measured in 590 (98%) patients (median age 33 [25-41] years, 42% women). After a median follow-up of 5.8 [IQR 5.1-6.2) years, 225 (38.5%) reached the primary endpoint. sST2 was significantly associated with the primary endpoint when adjusted for age, sex, creatinine and N terminal pro-B type brain natriuretic peptide (NT-proBNP) (HR per twofold higher sST2: 1.28, 95% CI 1.03 to 1.58, p=0.025). This association negated when adjusted for clinical variables and NT-proBNP (HR per twofold higher sST2: 1.19, 95% CI 0.96 to 1.48, p=0.106). Stratified analysis in complex ACHD did show a significant association between sST2 and the primary endpoint when adjusted for clinical variables and NT-proBNP (HR per twofold higher sST2: 1.31, 95% CI 1.01 to 1.69, p=0.043). Sex-specific analysis showed an association between sST2 and the primary endpoint in women (HR per twofold higher sST2 1.80, 95% CI 1.30 to 2.49, p<0.001) but not in men (HR per twofold higher sST2 1.19, 95% CI 0.90 to 1.56, p=0.223). CONCLUSIONS: sST2 is a promising novel biomarker in patients with ACHD, specifically in complex ACHD and women. Future research is warranted to elucidate sex-specific and diagnosis-specific differences.
引用
- Geenen LW, Baggen VJM, van den Bosch AE, et al. Prognostic value of soluble ST2 in adults with congenital heart disease. Heart. 2019. PMID: 30700520. doi:10.1136/heartjnl-2018-314168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。